Skip to main content
logo
Calidi Biotherapeutics, Inc. (CLDI)
NYSEAMERICAN: CLDI · Real-Time Price · USD
1.640
+0.147 (9.85%)
At close: Jul 31, 2026, 4:00 PM EDT
1.700
+0.060 (3.66%)
Pre-market: Aug 3, 2026, 5:56 AM EDT

Calidi Biotherapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
----0.050.45
Revenue Growth
-----89.98%-
Cost of Revenue
----0.010.09
Gross Profit
----0.030.36
Selling, General & Admin
9.4710.512.915.9815.96.16
Research & Development
9.99.748.8813.017.264.67
Total Operating Expenses
19.3720.2421.7828.9923.1610.84
Operating Income
-19.37-20.24-21.78-28.99-23.13-10.48
Interest Income
-0.050.182.89--
Interest Expense
-0.17-0.21-0.93-1.07-0.16-0.61
Other Non-Operating Income (Expense)
0.070.350.33-2.02-2.130.17
Total Non-Operating Income (Expense)
-0.110.19-0.42-0.21-2.29-0.44
Pretax Income
-19.09-20.05-22.2-29.2-25.42-10.92
Provision for Income Taxes
0.020.020.010.020.010.01
Net Income
-19.11-20.06-22.21-29.22-25.43-10.93
Minority Interest in Earnings
-0.08-0.16-0.07---
Net Income Attributable to Preferred Dividends
5.985.671.67---
Net Income to Common
-25.01-25.58-23.81-29.22-25.43-10.93
Net Income Growth
------
Shares Outstanding (Basic)
000--0
Shares Outstanding (Diluted)
000--0
Shares Change
445.05%544.98%----
EPS (Basic)
-66.88-95.20-571.20---1056.00
EPS (Diluted)
-66.88-95.20-571.20---1056.00
EPS Growth
------
Free Cash Flow
-18.4-21.41-19.71-27.57-13.64-7.98
Free Cash Flow Growth
------
Free Cash Flow Per Share
-46.69-79.64-472.80---775.86
Gross Margin
----68.89%79.06%
Operating Margin
-----51395.60%-2334.52%
Profit Margin
-----56504.40%-2434.97%
FCF Margin
-----30315.60%-1777.28%
EBITDA
-17.68-18.59-20.24-27.74-22.88-10.33
EBITDA Margin
-----50833.30%-2299.78%
EBIT
-19.37-20.24-21.78-28.99-23.13-10.48
EBIT Margin
-----51395.60%-2334.52%
Effective Tax Rate
-0.08%-0.07%-0.06%-0.05%-0.04%-0.10%
SEC Filings: 10-K · 10-Q